According to the most recent 13F filing that Hunter Perkins Capital Management LLC submitted with the Securities and Exchange Commission, the firm’s holdings in Bristol-Myers Squibb (NYSE: BMY) were cut by 40.2% during the fourth quarter.
The company had 46,310 shares of the biopharmaceutical company’s stock at the end of the period after selling 31,100 shares.
According to the most recent report that Hunter Perkins Capital Management LLC submitted to the Securities and Exchange Commission, the company’s holding in Bristol-Myers Squibb was valued at $3,332,000.
Recently, several other significant institutional investors have adjusted the stocks they are currently holding.
During the third quarter, Vanguard Group, INC increased the percentage of Bristol-Myers Squibb stock owned by 1.6%.
After acquiring an additional 3,058,491 shares over the period in question, Vanguard Group INC currently has a total of 199,886,585 shares of the biopharmaceutical firm, which gives the company a value of $14,209,937,000.
BlackRock INC boosted its holdings in Bristol-Myers Squibb by 2% during the third quarter of this fiscal year.
BlackRock INC now owns 174,002,852 shares of the biopharmaceutical company’s stock after purchasing an additional 3,357,590 shares.
The current market value of these shares is $12,369,862,000.
During the second quarter, FMR LLC grew its holdings in Bristol-Myers Squibb by 7.2 percent.
After acquiring 4,855,169 additional shares during the preceding quarter, FMR LLC now holds 71,882,436 shares of the biopharmaceutical business, valued at $5,534,947,000.
During the second quarter, Northern Trust Corp.
Boosted the percentage of Bristol-Myers Squibb stock owned by 1.9%.
After purchasing 463,344 shares in the preceding quarter, Northern Trust Corp. now owns 24,550,030 shares of the biopharmaceutical company, valued at a total of $1,890,352,000.
Last but not least, during the second quarter, Legal & General Group Plc increased the percentage of Bristol-Myers Squibb stock owned by 4.1%.
In the most recent quarter, Legal & General Group Plc purchased 674,921 additional shares of the biopharmaceutical firm, bringing its total number of shares owned to 17,053,158, with a value of $1,313,100,000. Currently, 75.51% of the stock is owned by institutional investors.
In other news, on Monday, February 6th, the Chief Executive Officer, Giovanni Caforio, sold 240,000 shares.
At an average price of $74.65, the shares could fetch a total of $17,916,000.00 when sold.
As a result of the transaction, the chief executive officer now owns 236.104 shares of the firm, which are about $17.625,163.60. You can learn more about the transaction by following the link in the previous sentence, which takes you to a document submitted to the Securities and Exchange Commission. On February 6th, the company’s Chief Executive Officer, Giovanni Caforio, sold 240,000 shares of the company’s stock.
At an average price of $74.65, the shares could fetch a total of $17,916,000.00 when they were put up for sale.
As a result of the sale, the chief executive officer now owns 236.104 business shares, which have an approximate value of $17.625,163.60.
The transaction was made public via a filing submitted to the Securities and Exchange Commission (SEC), which may be on the SEC’s website. On February 6th, Executive Vice President Ann Powell sold 11,183 shares of the company’s stock.
The stock sale resulted in a revenue of $835,258.27, corresponding to an average price of $74.69 per share. Following the successful completion of the sale, the executive vice president currently possesses 23,043 shares of the company’s stock, which together have a value of $1,721,081.67.
The disclosure for this sale can be found at this location. Company insiders hold just 0.09% of the company’s stock.
Recently, BMY has attracted the attention of several different brokerage houses. Cantor Fitzgerald released its first report on Bristol-Myers Squibb on the 17th of January.
They recommended an “overweight” position for the stock and set a price objective of $95.00. On Monday, March 6th, Bristol-Myers Squibb was included in the coverage provided by Jefferies Financial Group.
They recommended that investors “hold” onto the shares and set the price target at $62.00. On Thursday, March 16th, Bristol-Myers Squibb was included in the coverage that StockNews.com provides.
They suggested that investors “strongly purchase” the stock.
Atlantic Securities increased their price objective on Bristol-Myers Squibb from $88.00 to $90.00 and gave the stock an “overweight” rating in a report released on Friday, February 3rd. Finally, Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $70.00 to $78.00.
It gave the company an “equal weight” rating in a research note that was published on Tuesday, January 3rd. One equity research analyst has assigned a recommendation of “sell” to the stock, seven have assigned a rating of “hold,” seven have assigned a level of “buy,” and one has assigned a rating of “strong buy” to the stock.
According to Bloomberg.com, the firm is presently rated as a “Moderate Buy” on average, and the consensus price objective for the stock is set at $79.69.
On Wednesday, the BMY stock price remained at $67.51 a share. Compared to the daily average volume of 8,343,543, the stock was traded for 1,280,385 shares.
The simple moving average for the stock over the past 50 days is $70.81, and the simple moving average over the past 200 days is $72.93.
The business’s market capitalization is currently sitting at $141.69 billion, while its P/E ratio is 22.98, its price-to-earnings-growth ratio is 1.45, and its beta value is 0.46.
The company has 1.13 times as much debt as equity, 1.25 times the current ratio, and 1.14 times the quick ratio.
The price of Bristol-Myers Squibb hit a 52-week low of $65.28, while it reached a 52-week high of $81.43.
On Thursday, February 2nd, Bristol-Myers Squibb (NYSE: BMY) disclosed its earnings to the public.
The biopharmaceutical company announced earnings per share for the quarter of $1.82, $0.11 higher than the $1.71 analysts had anticipated.
The revenue for the quarter came in at $11.41 billion, which is significantly more than the analysts’ projection of $11.20 billion.
The return on equity for Bristol-Myers Squibb was 51.60%, and the company’s net margin was 13.71%.
The company’s revenue fell by 4.8% compared to the previous year.
The previous year’s results showed that the company earned $1.83 per share.
According to projections made by equity research experts, Bristol-Myers Squibb will generate $8.06 per share in 2018.
In addition, the company has announced a quarterly dividend, which is scheduled to be distributed on the first Monday in May. Shareholders of record on the 10th of April will receive a dividend payment of $0.57.
This translates to a dividend payment of $2.28 annually and a dividend yield of 3.38%.
The date the dividend will be paid out before it is distributed is April 6. 77.29% of Bristol-Myers Squibb’s profits are distributed to shareholders.
Discussion about this post